Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels


Biological E. Limited, a Hyderabad-based vaccine and pharmaceutical company, agreed to buy CpG 1018 adjuvant from Dynavax Technologies Corp. (DVAX) for use in the commercial production of Biological E's COVID-19 vaccine candidate, CORBEVAX.


RTTNews | Jul 6, 2021 08:25AM EDT

08:24 Tuesday, July 6, 2021 (RTTNews.com) - Biological E. Limited, a Hyderabad-based vaccine and pharmaceutical company, agreed to buy CpG 1018 adjuvant from Dynavax Technologies Corp. (DVAX) for use in the commercial production of Biological E's COVID-19 vaccine candidate, CORBEVAX.

The companies have extended their commercial supply agreement through 2022. The agreement includes doses for delivery in 2021, which were manufactured under the previously announced funding agreement between the Coalition for Epidemic Preparedness Innovations (CEPI) and Dynavax. Pending conditional regulatory approvals in India, Biological E expects to commence product launch of CORBEVAX later this year.

Last month, India's Union Ministry of Health finalized arrangements with Biological E. to reserve 300 million doses of CORBEVAX.

Read the original article on RTTNews ( https://www.rttnews.com/3207165/biological-e-to-buy-dynavax-s-cpg-1018-adjuvant-for-covid-19-vaccine-candidate.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved






Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC